ENSC

Ensysce Biosciences Inc

ENSC, USA

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

https://www.ensysce.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ENSC
stock
ENSC

New Brazil patent backs Ensysce bid for safer opioid pain drugs Stock Titan

Read more →
ENSC
stock
ENSC

Why analysts upgrade Crocs Inc. stock - CPI Data & Safe Swing Trade Setup Alerts bollywoodhelpline.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$19.225

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

High

2.49

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-309.89 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-117.29 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-403.53 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.92

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 6.55% of the total shares of Ensysce Biosciences Inc

1.

Perceptive Advisors LLC

(2.9196%)

since

2025/06/30

2.

Adage Capital Partners Gp LLC

(2.5168%)

since

2025/06/30

3.

Geode Capital Management, LLC

(0.3423%)

since

2025/06/30

4.

Fidelity Extended Market Index

(0.2752%)

since

2025/07/31

5.

FNY Investment Advisers, LLC

(0.1011%)

since

2025/06/30

7.

SBI Securities Co Ltd

(0.0787%)

since

2025/06/30

8.

Spartan Extended Market Index Pool F

(0.0688%)

since

2025/07/31

9.

Fidelity Series Total Market Index

(0.0559%)

since

2025/07/31

10.

Tower Research Capital LLC

(0.0461%)

since

2025/06/30

11.

Spartan Total Market Index Pool G

(0.0341%)

since

2025/07/31

12.

Morgan Stanley - Brokerage Accounts

(0.0127%)

since

2025/06/30

13.

UBS Group AG

(0.0119%)

since

2025/06/30

14.

BlackRock Inc

(0.0022%)

since

2025/06/30

15.

Bank of America Corp

(0.0006%)

since

2025/06/30

16.

NT Ext Equity Mkt Idx Fd - NL

(0.0004%)

since

2025/06/30

17.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0003%)

since

2025/06/30

18.

NT Ext Equity Mkt Idx Fd - L

(0.0001%)

since

2025/06/30

19.

Murchinson Ltd.

(0%)

since

2025/06/30

20.

Sabby Management LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-1.29

EPS Estimate

-0.93

EPS Difference

-0.36

Surprise Percent

-38.7097%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(1.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.